Summary:

- The article discusses the growing competition between the U.S. and China in the biotech and pharmaceutical industries, particularly in the context of drug deals and acquisitions.
- It highlights how the U.S. and China are vying for dominance in the global biotech market, with both countries actively pursuing partnerships, investments, and acquisitions to bolster their respective drug development pipelines and technological capabilities.
- The article also explores the potential implications of this geopolitical rivalry on the global pharmaceutical landscape, including concerns about technology transfer and intellectual property protection.